# Japan Genetic Testing Market

> Japan Genetic Testing Market Research Report By Type (Molecular Genetic Tests/ DNA Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests, Others), By Type (Prescribed Genetic Testing, Direct-to-Consumer Genetic Testing) and By Application (Reproductive Health, Cancer Screening Ancestry, Predictive and Pre-Symptomatic Testing, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.82%
- **2024:** $ 399 Million
- **2025:** $ 474.09 Million
- **2035:** $ 2,659 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Myriad Genetics (US), 23andMe (US), Genomic Health (US), BGI (CN), Fulgent Genetics (US)

**Report ID:** MRFR/LS/43266-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/japan-genetic-testing-market-44946

---

## Market Summary

## **Japan Genetic Testing Market Overview**

As per MRFR analysis, the Japan Genetic Testing Market Size was estimated at 336.0 (USD Million) in 2023.The Japan Genetic Testing Market Industry is expected to grow from 399.0(USD Million) in 2024 to 2,300.0 (USD Million) by 2035. The Japan Genetic Testing Market CAGR (growth rate) is expected to be around 17.263% during the forecast period (2025 - 2035).

**Key Japan Genetic Testing Market Trends Highlighted**

In Japan, the genetic testing market is experiencing significant growth driven by several key factors. A major market driver is the increasing awareness and acceptance of personalized medicine. With advancements in technology, there is a growing understanding among patients and healthcare professionals about the benefits of genetic testing for disease prevention and treatment strategies. This trend is also influenced by the Japanese government's push for precision medicine, supported by initiatives aiming to integrate genomic information into routine healthcare.

Moreover, as the aging population in Japan continues to rise, there is an increasing demand for genetic tests that can identify hereditary conditions and guide preventive healthcare measures.This demographic shift presents opportunities for companies to develop innovative genetic testing solutions that cater specifically to the needs of this population. The rise of health consciousness among Japanese consumers further drives demand for genetic testing as individuals seek to understand their genetic predispositions and optimize their health through informed lifestyle choices.

Recently, there has been a notable trend toward expanding access to genetic testing services, with more healthcare providers incorporating these tests into standard procedures. Public health campaigns and educational programs have increased awareness the importance of genetic testing in managing health risks.Additionally, collaborations between biotech companies and healthcare institutions are emerging, creating a conducive environment for the growth of genetic testing services. The integration of artificial intelligence in genetic testing analysis is also gaining momentum, further enhancing the accuracy and efficiency of test results.

Overall, the Japan genetic testing market is poised for development, shaped by evolving consumer preferences and innovative technological advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Japan Genetic Testing Market Drivers**

**Increasing Prevalence of Genetic Disorders**

The Japan Genetic Testing Market Industry is experiencing growth due to the rising prevalence of genetic disorders among the population. According to the Japanese Ministry of Health, Labour and Welfare, around 1 in 1,000 newborns are diagnosed with a genetic disorder, leading to heightened demand for genetic testing services.

Additionally, the increase in awareness about conditions such as Huntington's disease and cystic fibrosis has prompted many individuals to seek genetic testing for early diagnosis and management.Organizations like the Japanese Society of Human Genetics play a crucial role in spreading awareness and research in this field, contributing to significant growth in the genetic testing market.

**Government Support for Genetic Research**

The Japanese government has been actively supporting genetic research and testing initiatives, which plays a significant role in boosting the Japan Genetic Testing Market Industry. In recent years, substantial funding has been allocated to projects focused on understanding genetic diseases and enhancing diagnostic solutions. For instance, the Japan Agency for Medical Research and Development (AMED) has invested heavily in genomic medicine research.Such government initiatives help researchers and companies develop innovative genetic tests, leading to increased availability and accessibility in the market, ultimately driving growth.

**Technological Advances and Innovations**

Technological advancements in genetic testing, such as Next-Generation Sequencing (NGS) and improved bioinformatics tools, have significantly contributed to the growth of the Japan Genetic Testing Market Industry. The introduction of NGS technology has reduced the cost and time required for genetic testing, making it more accessible to the population.

According to a report by the Ministry of Economy, Trade and Industry, the NGS market in Japan is expected to expand rapidly, reaching a market size of trillions of yen by 2025.Established companies like Takara Bio Inc. are leading the way with their innovative solutions, fostering a competitive environment that further enhances the market.

**Growing Awareness and Demand for Personalized Medicine**

As awareness about personalized medicine continues to grow in Japan, the demand for genetic testing is also increasing. Personalized medicine allows healthcare providers to tailor medical treatment to the individual characteristics of each patient, which is heavily reliant on genetic information. Surveys conducted by the Japanese Medical Association indicate that over 70% of healthcare professionals support the integration of genetic testing in treatment plans.Furthermore, collaborations between pharmaceutical companies and genetic testing providers, such as the joint ventures initiated by Takeda Pharmaceutical Company, aim to develop medicines based on patients' genetic profiles, further propelling the market forward.

**Japan Genetic Testing Market Segment Insights**

**Genetic Testing Market Type Insights**

The Japan Genetic Testing Market is thriving, with a notable focus on various types of testing methodologies that cater to rising public interest and demand in genetic analytics. Among these, Molecular Genetic Tests, particularly DNA Tests, play a pivotal role as they allow for the detection of specific genetic conditions and predispositions, significantly aiding in early diagnosis and personalized medicine. This testing type harnesses advanced techniques to analyze genes at a molecular level, making it essential for both clinicians and patients seeking tailored healthcare solutions.

Chromosomal Genetic Tests, on the other hand, are vital for identifying abnormalities in chromosomes that may lead to genetic disorders or conditions. Such tests help in prenatal screening and are instrumental in guiding reproductive choices, reflecting society's growing awareness genetic health in a country with an aging population.

Biochemical Genetic Tests also hold significance as they assess the functioning of genes related to metabolic pathways, offering insights into inherited metabolic disorders. This segment underscores the advancements in neonatal screening programs in Japan, where early detection can significantly impact treatment outcomes. Lastly, the category of Others encompasses emerging testing techniques and innovative approaches that may not be captured under the traditional classifications, showcasing a dynamic and evolving genetic landscape.

Statistics related to the Japan Genetic Testing Market indicate a thriving scene driven by technological advancements and increasing awareness among the population. The focus on these testing types not only exemplifies the growing reliance on genetic testing for preventative healthcare but also underscores the ongoing investment in research and development within the country. With supportive government policies and initiatives aimed at enhancing healthcare technologies, there exists considerable opportunity for growth across these varied testing types, addressing both public health concerns and individual healthcare needs.

The overall market is greatly influenced by the population's increasing emphasis on personalized healthcare solutions and advancements in genetic research, ensuring these genetic testing types remain relevant and significant in the Japanese healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Genetic Testing Market Type Insights**

The Japan Genetic Testing Market encompasses various types, with Prescribed Genetic Testing and Direct-to-Consumer Genetic Testing capturing significant attention. Prescribed Genetic Testing is typically utilized within healthcare settings, where patients may undergo tests based on clinical recommendations. This segment greatly emphasizes personalized medicine, allowing healthcare providers to tailor treatments based on genetic profiles, which aligns with Japan's focus on advancing healthcare technology and improving patient outcomes. On the other hand, Direct-to-Consumer Genetic Testing offers consumers easy access to genetic insights without the need for healthcare intermediaries.

This segment has gained traction due to rising consumer awareness and interest in personal genomics, enabling individuals to make informed lifestyle choices based on their genetic predispositions. While Prescribed Genetic Testing holds a majority share within the clinical landscape, the growing acceptance of Direct-to-Consumer options suggests a dynamic shift in consumer behavior. As the Japan Genetic Testing Market continues to evolve, both segments are projected to play crucial roles in enhancing health management capabilities and empowering individuals with knowledge about their genetic backgrounds.

**Genetic Testing Market Application Insights**

The Application segment of the Japan Genetic Testing Market plays a crucial role in addressing various healthcare needs and personal preferences within the nation. The demand for genetic testing services is built upon the increasing awareness of genetic disorders and the rising prevalence of chronic diseases among the Japanese population. Reproductive health services are significant as they empower families to make informed decisions about their offspring's health and hereditary conditions.

Additionally, cancer screening is of paramount importance due to Japan's aging population, as early genetic testing can lead to timely intervention and treatment options.Predictive and pre-symptomatic testing aids individuals in understanding their genetic predispositions, leading to proactive health management. Furthermore, ancestry testing has gained traction, reflecting a societal interest in heritage and lineage, intertwining personal identity with broader healthcare discussions. As the Japan Genetic Testing Market expands, these applications are expected to innovate, driven by advances in technology and an increasing demand for personalized medicine.

Overall, Japan's robust healthcare system and emphasis on preventive care further support the growth of these application areas in the genetic testing landscape.

**Japan Genetic Testing Market Key Players and Competitive Insights**

The Japan Genetic Testing Market is characterized by a rapidly evolving landscape that integrates advanced technology, substantial investment, and increasing consumer awareness about genetic health. The competitive environment is shaped by a mixture of established pharmaceutical companies, biotechnology startups, and research institutions, all striving to leverage genetic testing as a transformative tool for disease prevention, diagnosis, and personalized medicine. With rising demand driven by increasing incidences of genetic disorders and an aging population, companies are focusing on innovation, collaboration, and strategic partnerships to enhance their offerings and maintain a competitive edge in this dynamic marketplace.

Key players are also responding to regulatory changes and healthcare policies that encourage genetic testing to improve healthcare outcomes, further intensifying competition among market participants.Mitsubishi Tanabe Pharma is a key competitor in the Japan Genetic Testing Market, recognized for its innovative approaches and extensive research capabilities. The company has established a robust presence by focusing on developing advanced diagnostic tools and genetic testing solutions tailored to the needs of the Japanese population. Mitsubishi Tanabe Pharma's strengths lie in its integration of genetic testing within therapeutic areas, allowing for tailored treatments that align with patients' genetic profiles.

The company's commitment to quality and regulatory compliance ensures that its products meet the highest standards in the industry. Additionally, it collaborates with leading research institutions and healthcare providers, enhancing its capabilities and expanding its reach in the genetic testing sector.Gene Techno Science has emerged as a significant player within the Japan Genetic Testing Market, offering cutting-edge solutions focused on genetic testing services and products. The company specializes in providing genetic testing for various conditions, from hereditary diseases to pharmacogenetics, thereby addressing critical needs in personalized medicine.

Its strengths include a strong focus on research and development, which has led to innovative testing methodologies that are both efficient and reliable. Gene Techno Science's market presence is bolstered by strategic partnerships and collaborations with other firms in the biotechnology and pharmaceutical industries, allowing it to expand its offerings and enhance market penetration. The company has engaged in various mergers and acquisitions that have strengthened its portfolio and improved its competitive positioning within Japan, enabling it to better serve a growing clientele seeking personalized genetic insights.

**Key Companies in the Japan Genetic Testing Market Include**

**Japan Genetic Testing Market Industry Developments**

In recent months, the Japan Genetic Testing Market has seen significant advances, particularly with companies like Mitsubishi Tanabe Pharma and Fujifilm Holdings increasing their focus on genetic therapies and testing-related solutions. In October 2023, Gene Techno Science announced the expansion of its genomic research capabilities, aligning with the Japanese government’s push for personalized medicine initiatives. Myriad Genetics is also expanding its market presence, collaborating with local healthcare providers to enhance genetic screening services.

Notably, in September 2023, 23andMe launched a new saliva-based genetic testing kit tailored for Japanese consumers, responding to the rising demand for personalized health insights. Mergers and acquisitions have been prominent, with Roche acquiring a minority stake in Nippon Gene in August 2023, enhancing its foothold in the Asian market. The overall growth trajectory is influenced by a surge in healthcare spending and rising awareness about genetic disorders among the population, with an estimated market valuation expected to rise significantly. Key players like Illumina continue to invest heavily in R&D to keep pace with innovations in genetic testing technologies.

The Japanese Genetic Testing Market is on an upward trajectory, underscoring the importance of genetics in healthcare.

**Japan Genetic Testing Market Segmentation Insights**

## Market Drivers

### Regulatory Framework Enhancements

The regulatory landscape surrounding the genetic testing market is evolving, which serves as a crucial driver for market growth. Recent enhancements in regulations aim to ensure the safety and efficacy of genetic tests, fostering consumer confidence. These regulations also encourage innovation by providing clear guidelines for companies operating in the genetic testing market. As a result, businesses are more likely to invest in research and development, leading to the introduction of new and improved testing solutions. The regulatory framework is expected to support a market expansion of around 12% annually, reflecting the positive impact of a robust regulatory environment on the genetic testing market.

### Rising Demand for Personalized Medicine

the genetic testing market is experiencing a notable surge in demand for personalized medicine. This trend is driven by an increasing recognition of the importance of tailored healthcare solutions that cater to individual genetic profiles. As healthcare providers and patients alike seek more effective treatment options, the market for genetic testing is projected to grow significantly. According to recent estimates, the market could reach approximately $1.5 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 10%. This shift towards personalized medicine not only enhances patient outcomes but also drives innovation within the genetic testing market, as companies strive to develop more precise and efficient testing methodologies.

### Advancements in Genetic Research and Technology

the genetic testing market is significantly influenced by advancements in genetic research and technology. Innovations such as next-generation sequencing (NGS) and CRISPR technology are revolutionizing the capabilities of genetic testing, enabling more accurate and comprehensive analyses. These technological advancements not only enhance the reliability of test results but also expand the range of conditions that can be tested. As a result, the market is expected to grow, with projections indicating a potential increase in market size by 15% annually over the next five years. This growth is indicative of the ongoing evolution within the genetic testing market, driven by continuous research and development efforts.

### Growing Aging Population and Genetic Testing Awareness

Japan's aging population is a significant driver for the genetic testing market. As the demographic shifts towards an older population, there is an increasing prevalence of age-related diseases, which necessitates more comprehensive healthcare solutions. Genetic testing offers valuable insights into hereditary conditions, allowing for better management of health risks associated with aging. Furthermore, public awareness campaigns are enhancing understanding of genetic testing's benefits, leading to higher adoption rates among older adults. It is anticipated that the aging population could contribute to a market growth of approximately 20% by 2027, underscoring the critical role of demographic trends in shaping the genetic testing market.

### Integration of Genetic Testing in Preventive Healthcare

Preventive healthcare is becoming increasingly integrated with genetic testing in Japan, which is a key driver for the market. As awareness of genetic predispositions to various diseases grows, healthcare professionals are incorporating genetic testing into routine health assessments. This proactive approach allows for early detection and intervention, potentially reducing healthcare costs in the long run. The genetic testing market is likely to benefit from this trend, as more individuals opt for testing to understand their health risks. It is estimated that the preventive healthcare segment could account for over 30% of the overall genetic testing market by 2025, highlighting the importance of this integration in shaping future healthcare practices.

## Future Outlook

The [Genetic Testing Market](https://www.marketresearchfuture.com/reports/genetic-testing-market-2009) in Japan is projected to grow at an 18.82% CAGR from 2025 to 2035, driven by technological advancements, increasing healthcare awareness, and personalized medicine trends.

**New opportunities:**

- Development of AI-driven genetic analysis platforms
- Expansion of direct-to-consumer genetic testing services
- Partnerships with healthcare providers for integrated testing solutions

By 2035, the genetic testing market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Application: Prenatal Testing (Largest) vs. Newborn Screening (Fastest-Growing)

In the Japan genetic testing market, the application segment has notable distinctions in market share among its various values. Prenatal Testing holds the largest segment, often preferred for its crucial insights into fetal health and genetic conditions. Newborn Screening follows as a rapidly expanding sector, gaining traction due to increasing awareness and legislation mandating screenings for serious genetic disorders. Both segments illustrate the critical role of genetic testing in early health interventions.

Growth trends indicate a profound shift towards more personalized medicine and preventative healthcare, driving the demand for genetic testing applications. The integration of advanced technologies, such as next-generation sequencing, further enhances the precision and efficiency of these tests. Additionally, healthcare initiatives emphasizing early diagnosis, coupled with rising consumer awareness, significantly fuel the expansion of these segments in the market.

Prenatal Testing: Dominant vs. Carrier Testing: Emerging

Prenatal Testing is recognized as the dominant force in the application segment, primarily due to its established reputation and the vital information it provides regarding fetal health. This category continues to thrive, driven by technological advancements that enhance testing accuracy and accessibility. On the other hand, Carrier Testing is emerging as a pivotal aspect of genetic testing, focusing on assessing the risk of passing genetic disorders to offspring. Its growth is influenced by increasing familial awareness regarding hereditary conditions and the societal shift towards proactive health management. As education and accessibility improve, Carrier Testing is expected to capture a larger share within the genetic testing landscape, complementing the established Prenatal Testing.

### By Type: Whole Genome Sequencing (Largest) vs. Non-Invasive Prenatal Testing (Fastest-Growing)

The market for genetic testing is diverse, with several valuable segment types contributing to its overall dynamics. Whole Genome Sequencing holds the largest share among these segments, driven by its comprehensive analysis capabilities that appeal to a wide range of consumers and healthcare providers. In comparison, Non-Invasive Prenatal Testing is rapidly gaining traction, capturing a significant share as more expectant parents seek risk-free options for prenatal screening.

Growth trends in the Japan genetic testing market are largely driven by advancements in technology and rising awareness of genetic disorders. Panel Tests and Whole Exome Sequencing are also playing a critical role in catering to specific genetic conditions, while Single Gene Tests continue to be essential for targeted genetic analysis. The increasing demand for personalized medicine further propels these segments, influencing market evolution toward more innovative solutions.

Whole Genome Sequencing (Dominant) vs. Non-Invasive Prenatal Testing (Emerging)

Whole Genome Sequencing is characterized by its ability to provide a comprehensive overview of a person’s entire genetic makeup, making it a dominant player in the market. Its widespread adoption among research institutions and healthcare providers is bolstered by advancements in sequencing technologies that make it more accessible and affordable. On the other hand, Non-Invasive Prenatal Testing is emerging as a significant segment due to its non-invasive nature, allowing for safer prenatal screening without risks to the fetus. This method is particularly appealing to parents looking for early detection of genetic abnormalities with minimal risk, thus driving its rapid growth. Both segments represent critical advancements in genetic testing, reflecting the market's shift towards more precise and patient-centric options.

### By Service Type: Laboratory Services (Largest) vs. Consultation Services (Fastest-Growing)

The Japan genetic testing market reveals a strong market share distribution, with Laboratory Services leading the segment significantly. This dominance is attributed to the advanced technology and robust infrastructure supporting these services, making them the preferred choice for many consumers seeking reliable genetic testing. Diagnostic Services follow closely, providing essential insights into genetic conditions, while Consultation Services are establishing their presence, offering personalized advice and interpretation of test results to customers seeking clarity.

Looking ahead, the growth trends in this segment are promising, driven by increasing awareness about genetic disorders and advancements in testing technology. The rise of personalized medicine and growing demand for preventive healthcare services are accelerating the adoption of Consultation Services, identified as the fastest-growing segment. Furthermore, industry innovations and improving accessibility are shaping the competitive landscape, positioning various service types for continued growth in the evolving Japan genetic testing market.

Laboratory Services (Dominant) vs. Consultation Services (Emerging)

Laboratory Services are characterized by their extensive capabilities and state-of-the-art facilities, allowing for a wide array of genetic tests that cater to various needs, including predictive testing and carrier testing. Their established reputation and reliability position them as the dominant player in the market, leveraging advanced technologies. In contrast, Consultation Services are emerging as a crucial aspect of genetic testing, focusing on the interaction between professionals and clients. They provide tailored advice based on test outcomes, helping individuals navigate their results with confidence. As more consumers pursue personalized genetic insights, the demand for Consultation Services continues to surge, highlighting a significant shift towards holistic care in the Japan genetic testing market.

### By End User: Hospitals (Largest) vs. Clinical Laboratories (Fastest-Growing)

In the Japan genetic testing market, hospitals represent the largest end user segment, significantly influencing the overall market dynamics. Clinical laboratories also play a crucial role, demonstrating rapid growth potential. Research institutions and homecare settings, although present, contribute less to market share than these two segments. The competition between hospitals and clinical laboratories shapes the service landscape, prompting enhancements in genetic testing services. 

The growth trends in this segment are driven by increasing awareness of genetic testing benefits among healthcare providers and patients. Hospitals are investing in advanced testing technologies to improve diagnostic accuracy, while clinical laboratories are expanding their service offerings to meet rising demand. Additionally, government initiatives supporting genetic research and personalized medicine are contributing to an upsurge in testing services, positioning clinical laboratories as a key player in the evolving landscape.

Hospitals (Dominant) vs. Clinical Laboratories (Emerging)

Hospitals dominate the Japan genetic testing market due to their extensive resources, established patient bases, and comprehensive healthcare services. They offer a wide range of genetic tests, facilitated by partnerships with leading technology firms, which enhances their service delivery. Conversely, clinical laboratories are emerging as competitive players, focusing on specialized genetic testing and personalized medicine. They are leveraging technological advancements to streamline testing processes, reduce turnaround times, and provide cost-effective solutions. The growing trend of direct-to-consumer genetic testing is also fueling the demand for clinical laboratories, allowing them to capture a larger market share as they adapt to consumer needs. Thus, while hospitals maintain dominance, clinical laboratories are poised for substantial growth.

## Competitive Benchmarking

The genetic testing market in Japan is characterized by a dynamic competitive landscape, driven by technological advancements and increasing consumer awareness regarding personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Roche (CH) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Illumina (US) focuses on next-generation sequencing technologies, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of genetic testing solutions. Roche (CH) is strategically positioned through its integration of diagnostics and pharmaceuticals, which allows for a comprehensive approach to genetic testing. Collectively, these strategies foster a competitive environment that is increasingly focused on innovation and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements. This competitive structure encourages smaller firms to innovate and differentiate their offerings, thereby contributing to a vibrant market ecosystem.

In October  Illumina (US) announced a partnership with a leading Japanese healthcare provider to expand access to its genomic sequencing services. This collaboration is expected to enhance patient care by integrating advanced genetic testing into routine clinical practice, thereby positioning Illumina (US) as a key player in the Japanese market. The strategic importance of this partnership lies in its potential to increase market penetration and foster innovation in personalized medicine.

In September  Roche (CH) launched a new genetic testing platform aimed at improving the accuracy of hereditary cancer risk assessments. This platform utilizes advanced algorithms and machine learning to analyze genetic data more effectively. The introduction of this technology signifies Roche's commitment to enhancing diagnostic capabilities and reflects a broader trend towards the integration of AI in genetic testing, which may lead to improved patient outcomes.

In August  Thermo Fisher Scientific (US) expanded its product offerings by acquiring a local genetic testing company in Japan. This acquisition is likely to bolster Thermo Fisher's market position by providing access to established distribution channels and local expertise. The strategic move underscores the importance of regional expansion in a competitive landscape where localized knowledge can significantly enhance operational effectiveness.

As of November  current trends in the genetic testing market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological innovation, supply chain reliability, and the ability to deliver personalized solutions. This transition may redefine market dynamics, as companies that prioritize these aspects are likely to gain a competitive edge.

## Recent News & Developments

In recent months, the Japan Genetic Testing Market has seen significant advances, particularly with companies like Mitsubishi Tanabe Pharma and Fujifilm Holdings increasing their focus on genetic therapies and testing-related solutions. In October 2023, Gene Techno Science announced the expansion of its genomic research capabilities, aligning with the Japanese government’s push for personalized medicine initiatives. Myriad Genetics is also expanding its market presence, collaborating with local healthcare providers to enhance genetic screening services.

Notably, in September 2023, 23andMe launched a new saliva-based genetic testing kit tailored for Japanese consumers, responding to the rising demand for personalized health insights. Mergers and acquisitions have been prominent, with Roche acquiring a minority stake in Nippon Gene in August 2023, enhancing its foothold in the Asian market. The overall growth trajectory is influenced by a surge in healthcare spending and rising awareness about genetic disorders among the population, with an estimated market valuation expected to rise significantly. Key players like Illumina continue to invest heavily in R&D to keep pace with innovations in genetic testing technologies.

The Japanese Genetic Testing Market is on an upward trajectory, underscoring the importance of genetics in healthcare.

## Report Scope

| MARKET SIZE 2024 | 399.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 474.09(USD Million) |
| MARKET SIZE 2035 | 2659.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Abbott Laboratories (US), Myriad Genetics (US), 23andMe (US), Genomic Health (US), BGI (CN), Fulgent Genetics (US) |
| Segments Covered | Application, Type, Service Type, End User |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative genetic testing solutions in evolving regulatory landscapes. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the genetic testing market. |
| Countries Covered | Japan |

## Frequently Asked Questions

**Q: What was the market valuation of the Japan genetic testing market in 2024?**
A: The market valuation was $399.0 Million in 2024.

**Q: What is the projected market valuation for the Japan genetic testing market by 2035?**
A: The projected valuation for 2035 is $2659.0 Million.

**Q: What is the expected CAGR for the Japan genetic testing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 18.82% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the Japan genetic testing market?**
A: Key players include Illumina, Thermo Fisher Scientific, Roche, Abbott Laboratories, Myriad Genetics, 23andMe, Genomic Health, BGI, and Fulgent Genetics.

**Q: What segment had the highest valuation in the Japan genetic testing market in 2024?**
A: Diagnostic Testing had the highest valuation at $99.8 Million in 2024.

**Q: What is the projected valuation for Carrier Testing by 2035?**
A: The projected valuation for Carrier Testing is $350.0 Million by 2035.

**Q: How much is the market for Whole Genome Sequencing expected to grow by 2035?**
A: The market for Whole Genome Sequencing is expected to reach $700.0 Million by 2035.

**Q: What was the valuation of Non-Invasive Prenatal Testing in 2024?**
A: Non-Invasive Prenatal Testing had a valuation of $79.0 Million in 2024.

**Q: Which end user segment is projected to have the highest valuation by 2035?**
A: Clinical Laboratories are projected to have the highest valuation at $823.0 Million by 2035.

**Q: What is the expected growth in the market for Laboratory Services from 2024 to 2035?**
A: The market for Laboratory Services is expected to grow from $159.0 Million in 2024 to $1040.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-genetic-testing-market-44946*